LpathTo Present Nexus Phase 2 Study Data In Wet Age-Related Macular Degeneration At The 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day
SAN DIEGO, Nov. 5, 2015 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that data from the Nexus Phase 2 study of iSONEP will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day in Las Vegas, Nevada on Saturday, November 14 at 12:59 p.m. Pacific Time. Presenting the data in an oral presentation will be Thomas Ciulla, M.D., a Nexus investigator and practicing ophthalmologist and retinal surgeon in Indianapolis, IN.
In May, Lpath announced that iSONEP did not meet the primary or key secondary endpoints in the Nexus trial, a prospective, randomized, Phase 2 clinical trial conducted in the U.S. that enrolled 158 patients with wet age-related macular degeneration (wet AMD) who had been subresponsive to treatment with existing anti-vascular endothelial growth factor (VEGF) therapies. Nexus trial patients did not show any statistically significant improvement in visual acuity at day 120 when treated with iSONEP as an adjunctive or monotherapy. Lpath conducted further analyses of the data including additional anatomical endpoints to better understand the results from each arm of the trial, and those findings will be included in the presentation at the AAO Annual Meeting. The presentation slides will be made available on Lpath's website (www.lpath.com) following the meeting and the company also plans to host a conference call on Tuesday, November 17, 2015 at 2:00 p.m. Pacific Time to discuss the additional findings. Details for the conference call will be announced on Monday, November 16, 2015.
San Diego-based Lpath, Inc. (NASDAQ: LPTN) is the category leader in lipid-targeted therapeutics. The company's ImmuneY2 drug-discovery engine has the unique ability to generate therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease. The company has developed four drug candidates, has advanced the first two to mid-stage trials and built evidence to support its approach of targeting bioactive lipids to treat a wide range of diseases. For more information, visit www.lpath.com.
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include but are not limited to, statements regarding the Company's development plans, potential therapeutic uses for its drug candidates, and the timing for the Company to commence clinical trials of its drug candidates. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the final results of the Company's preclinical studies and clinical trials may be different from the Company's studies or interim data results and may not support further clinical development and/or the commercialization of its drug candidates; the Company may not successfully complete its existing and any additional clinical trials for its drug candidates on a timely basis, or at all; the Company may fail to obtain required governmental approvals for any of its drug candidates; and the Company may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K filed with the SEC on March 24, 2015 and its Quarterly Report on Form 10-Q filed with the SEC on Aug 11, 2015. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Chief Executive Officer
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lpath-to-present-nexus-phase-2-study-data-in-wet-age-related-macular-degeneration-at-the-2015-american-academy-of-ophthalmology-annual-meeting-retinal-subspecialty-day-300172983.html
SOURCE Lpath, Inc.